Literature DB >> 36094480

Pre-exposure Prophylaxis Discontinuation During the COVID-19 Pandemic Among Men Who Have Sex With Men in a Multisite Clinical Cohort in the United States.

William C Goedel1, Brooke G Rogers2, Yu Li1, Amy S Nunn3, Rupa R Patel4, Brandon D L Marshall1, Leandro A Mena5, Lori M Ward5, J Benjamin Brock5, Siena Napoleon6, Alexandra Zanowick-Marr6, Kate Curoe4, Ashley Underwood4, Catrell J Johnson5, Khadijra R Lockwood5, Philip A Chan3,6.   

Abstract

BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic continues to put strain on health systems in the United States, leading to significant shifts in the delivery of routine clinical services, including those offering HIV pre-exposure prophylaxis (PrEP). We aimed to assess whether individuals discontinued PrEP use at higher rates during the COVID-19 pandemic and the extent to which disruptions to usual clinical care were mitigated through telehealth.
METHODS: Using data from an ongoing prospective cohort of men who have sex with men (MSM) newly initiating PrEP in 3 mid-sized cities (n = 195), we calculated the rate of first-time discontinuation of PrEP use in the period before the COVID-19 pandemic and during the COVID-19 pandemic and compared these rates using incidence rate ratios (IRRs). Furthermore, we compared the characteristics of patients who discontinued PrEP use during these periods with those who continued to use PrEP during both periods.
RESULTS: Rates of PrEP discontinuation before the COVID pandemic and during the COVID-19 pandemic were comparable [4.29 vs. 5.20 discontinuations per 100 person-months; IRR: 1.95; 95% confidence interval (CI): 0.83 to 1.77]. Although no significant differences in the PrEP discontinuation rate were observed in the overall population, the rate of PrEP discontinuation increased by almost 3-fold among participants aged 18-24 year old (IRR: 2.78; 95% CI: 1.48 to 5.23) and by 29% among participants covered by public insurance plans at enrollment (IRR: 1.29; 95% CI: 1.03 to 5.09). Those who continued to use PrEP were more likely to have had a follow-up clinical visit by telehealth in the early months of the pandemic (45% vs. 17%).
CONCLUSIONS: In this study, rates of PrEP discontinuation were largely unchanged with the onset of the COVID-19 pandemic. The use of telehealth likely helped retain patients in PrEP care and should continue to be offered in the future.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36094480      PMCID: PMC9472808          DOI: 10.1097/QAI.0000000000003042

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.771


  22 in total

1.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Authors:  Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden
Journal:  N Engl J Med       Date:  2010-11-23       Impact factor: 91.245

2.  Iowa TelePrEP: A Public-Health-Partnered Telehealth Model for Human Immunodeficiency Virus Preexposure Prophylaxis Delivery in a Rural State.

Authors:  Angela B Hoth; Cody Shafer; Dena Behm Dillon; Randy Mayer; George Walton; Michael E Ohl
Journal:  Sex Transm Dis       Date:  2019-08       Impact factor: 2.830

3.  The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test.

Authors:  K Bush; D R Kivlahan; M B McDonell; S D Fihn; K A Bradley
Journal:  Arch Intern Med       Date:  1998-09-14

4.  A brief measure for assessing generalized anxiety disorder: the GAD-7.

Authors:  Robert L Spitzer; Kurt Kroenke; Janet B W Williams; Bernd Löwe
Journal:  Arch Intern Med       Date:  2006-05-22

Review 5.  Initiation, discontinuation, and restarting HIV pre-exposure prophylaxis: ongoing implementation strategies.

Authors:  Sarah E Rutstein; Dawn K Smith; Shona Dalal; Rachel C Baggaley; Myron S Cohen
Journal:  Lancet HIV       Date:  2020-08-27       Impact factor: 12.767

6.  Changes in Sexual Behavior, PrEP Adherence, and Access to Sexual Health Services Because of the COVID-19 Pandemic Among a Cohort of PrEP-Using MSM in the South.

Authors:  Sanjana Pampati; Kayla Emrick; Aaron J Siegler; Jeb Jones
Journal:  J Acquir Immune Defic Syndr       Date:  2021-05-01       Impact factor: 3.771

7.  Mixed-Methods Evaluation of the Incorporation of Home Specimen Self-Collection Kits for Laboratory Testing in a Telehealth Program for HIV Pre-exposure Prophylaxis.

Authors:  Emily E Chasco; Angela B Hoth; Hyunkeun Cho; Cody Shafer; Aaron J Siegler; Michael E Ohl
Journal:  AIDS Behav       Date:  2021-03-19

8.  Sex in the Era of COVID-19 in a U.S. National Cohort of Cisgender Men, Transgender Women, and Transgender Men Who Have Sex with Men: April-May 2020.

Authors:  Christian Grov; Fatima Zohra; Drew A Westmoreland; Chloe Mirzayi; Alexa D'Angelo; Matthew Stief; Sarah Kulkarni; Denis Nash; Adam W Carrico
Journal:  Arch Sex Behav       Date:  2021-11-29

9.  Geographic Differences in COVID-19 Cases, Deaths, and Incidence - United States, February 12-April 7, 2020.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-04-17       Impact factor: 17.586

10.  Impact of Coronavirus Disease 2019 (COVID-19) on Human Immunodeficiency Virus (HIV) Pre-exposure Prophylaxis Prescriptions in the United States-A Time-Series Analysis.

Authors:  Ya Lin A Huang; Weiming Zhu; Jeffrey Wiener; Athena P Kourtis; H Irene Hall; Karen W Hoover
Journal:  Clin Infect Dis       Date:  2022-08-24       Impact factor: 20.999

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.